Literature DB >> 74412

Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine.

J A Beisler.   

Abstract

The antitumor nucleoside, 5-azacytidine (5-AC), is best administered clinically by prolonged intravenous infusion to minimize toxic effects. In opposition to this administration technique is facile drug decomposition in aqueous formulations giving products of unknown toxicity. Analysis of 24-h-old water solutions of 5-AC with high-pressure liquid chromatography (HPLC) indicated a threefold mixture of 5-AC, N-(formylamidino)-N'-beta-D-ribofuranosylurea (RGU-CHO), and 1-beta-D-ribofuranosyl-3-guanylurea (RGU). Preparative HPLC allowed the isolation and subsequent identification of each component in the mixture, including RGU-CHO which until now has not been available for chemical and biological study. It was shown that RGU-CHO in water solution readily equilibrates to 5-AC and more slowly deformylates to give RGU irreversibly. The latter hydrolysis produce exhibited no pronounced toxicity when tested either in vitro or in vivo. Although RGU-CHO showed considerable antitumor activity against murine L1210 leukemia, hydrolysis studies indicated that all of the observed activity could be attributed to 5-AC formed by in vivo equilibration from RGU-CHO. Moreover, RGU-CHO seemed to impart to test animals a toxicity which was no greater than that anticipated from its ability to generate 5-AC.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 74412     DOI: 10.1021/jm00200a012

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  Chemical probes in plant epigenetics studies.

Authors:  Huiming Zhang; Bangshing Wang; Cheng-Guo Duan; Jian-Kang Zhu
Journal:  Plant Signal Behav       Date:  2013-06-27

2.  5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.

Authors:  Jonathan M Rawson; Richard H Heineman; Lauren B Beach; Jessica L Martin; Erica K Schnettler; Michael J Dapp; Steven E Patterson; Louis M Mansky
Journal:  Bioorg Med Chem       Date:  2013-08-20       Impact factor: 3.641

3.  Hypomethylating drugs efficiently decrease cytosine methylation in telomeric DNA and activate telomerase without affecting telomere lengths in tobacco cells.

Authors:  Eva Majerová; Miloslava Fojtová; Iva Mozgová; Miroslava Bittová; Jiří Fajkus
Journal:  Plant Mol Biol       Date:  2011-08-25       Impact factor: 4.076

4.  DNA Methylation Inhibitor Zebularine Confers Stroke Protection in Ischemic Rats.

Authors:  Hua Dock; Annette Theodorsson; Elvar Theodorsson
Journal:  Transl Stroke Res       Date:  2015-04-01       Impact factor: 6.829

5.  DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Authors:  Min Chen; Daniel Shabashvili; Akbar Nawab; Sherry X Yang; Lisa M Dyer; Kevin D Brown; Melinda Hollingshead; Kent W Hunter; Frederic J Kaye; Steven N Hochwald; Victor E Marquez; Patricia Steeg; Maria Zajac-Kaye
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

6.  DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

Authors:  Stela S Palii; Beth O Van Emburgh; Umesh T Sankpal; Kevin D Brown; Keith D Robertson
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

7.  In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.

Authors:  Yong Chen; Lisa Liu; Eric Laille; Gondi Kumar; Sekhar Surapaneni
Journal:  Cancer Chemother Pharmacol       Date:  2010-01-30       Impact factor: 3.333

8.  Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells.

Authors:  Jonathan C Cheng; Daniel J Weisenberger; Felicidad A Gonzales; Gangning Liang; Guo-Liang Xu; Ye-Guang Hu; Victor E Marquez; Peter A Jones
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

9.  Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.

Authors:  Madhavi Billam; Michele D Sobolewski; Nancy E Davidson
Journal:  Breast Cancer Res Treat       Date:  2009-05-21       Impact factor: 4.872

10.  Effective, homogeneous and transient interference with cytosine methylation in plant genomic DNA by zebularine.

Authors:  Tuncay Baubec; Ales Pecinka; Wilfried Rozhon; Ortrun Mittelsten Scheid
Journal:  Plant J       Date:  2008-10-30       Impact factor: 6.417

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.